Sun Pharma Advanced Research Company (SPARC) psoriasis drug, Vibozilimod (SCD-044), failed to meet primary endpoints in Phase ...

Sun Pharma Advanced Research share price tanked 20 per centa after Vibozilimod (SCD-044) studies failed to meet the primary ...

Sun Pharma Advanced Research Co. has told NDTV Profit that it expects no financial impact or need for fresh capital expenditure following the discontinuation of SCD-044 trials, with other pipeline ...

Sun Pharma's shares experienced a 0.47 per cent decline, trading at Rs 1,659.80, alongside the sharper fall in SPARC shares ...

Shares of Sun Pharma Advanced Research Company Ltd (SPARC) plunged nearly 20% on Wednesday on the NSE, after the company ...

Shares of Sun Pharma Advanced Research Company (SPARC), the research division of India’s largest pharmaceutical firm Sun Pharma, fell 19 per cent to Rs 158 each after unsatisfactory Phase 2 trial ...

SPARC share price plunged 20% following poor Phase 2 trial outcomes for SCD-044. The stock peaked at ₹186 but fell to ₹156.50 ...

Shares of Sun Pharma Advanced Research Company (SPARC) shares crashed significantly on Wednesday after the company announced ...

Sun Pharma disclosed that the drug did not meet primary endpoints in either study and as a result, the development of the SCD ...

Sun Pharma Advanced Research Company (SPARC) shares plummeted nearly 20% after its psoriasis drug, SCD-044, failed to meet primary endpoints in Phase 2 trials.

SPARC and its partner Sun Pharma said they will "evaluate the appropriate next steps", but the setback sent its shares tumbling nearly 18% on the BSE on Wednesday.

Sun Pharma Advanced Research Company (SPARC) dropped 18.63% to Rs 159.15 after the company announced disappointing results from a key clinical trial.